

## Index

### a

- abacavir* 393–394
- abiraterone acetate* 202
- ABT-239* 226
- ABT-450* 272–273
- ABT-493* 272–273
- ABT-546* 158–159
- 2-acetamido-5-bromopyridine 189
- active pharmaceutical ingredients (APIs)
  - 1,2-addition reactions 147
  - 1,4-addition reactions 291
  - asymmetric hydrogenation reaction 14
  - asymmetric synthetic methods 11
  - bicyclic  $\beta$ -lactams 12
  - biotransformation 20
  - carbonic anhydrase inhibitor 20
  - carbonyl groups 13
  - catalytic synthesis 20
  - CBS reduction 15
  - cycloaddition reactions 291
  - cyclopropanation reaction 11
  - homogeneous catalytic hydrogenation 12
  - Jacobsen–Katsuki epoxidation 15
  - Merck's synthesis 12
  - Mizoroki–Heck reaction 18
  - multi-functional groups and stereocenters 11
  - Ru catalyst 13
  - Ru-I-SegPhos catalyst 13
  - Sharpless–Katsuki epoxidation 16
  - Sharpless–Katsuki system 17
  - sulphide asymmetric oxidation 18
- acyclovir* 394
- 1,2-addition reactions
  - acetalization 154
  - asymmetric catalytic aldol reaction 154
  - AZD5423* synthesis 156
  - C–C bond formation 148
  - Cu-catalyzed asymmetric addition 148
  - (+)-*discodermolide* 150
  - enantioenriched alcohols 149
  - FR901512* synthesis 150
  - halichondrins 150
  - HIV-1 protease inhibitors 152
  - NHK reactions 150
  - (+)-*preussin* 156
  - (*R*)-*salmeterol* 154
  - (*R*)-*tembamide* 155
  - saturated alcohols/dienes 149
- 1,4-addition reactions
  - ABT-546* 158
  - arylboron species 160
  - conjugate addition/dehydrative cyclization reaction 161
  - continuous flow processes 162
  - dinoprost* and *tafluprost* 159
  - (-)-*epibatidine* 170
  - erogorgiaene* 168
  - HVC drug development 167
  - (-)-*paroxetine* 163
  - prostaglandins 165
  - (*R*)- and (*S*)-*rolipram* 164
  - telcagepant* 169

- 1,4-addition reactions (*contd.*)  
*warfarin* 162  
 Zn-catalyzed diastereoselective  
 Michael reaction 164  
*adrenaline* 85  
*ALB 109780* 218–219  
 alcohol dehydrogenases (ADHs) 394  
*aliskiren* 23, 79–80, 275–277  
 alkenes, enamides 77  
 allylic substitution reactions 234  
*almorexant* (ACT-078573A) 93  
 $\alpha$ -amino acids 393  
 (*S*)- $\alpha$ -aminoindane synthesis 392  
 $\alpha$ -arylenol acetates 82  
 $\alpha$ -chiral aldehyde 408  
 $\alpha$ -chloro ketone 397  
 (–)- $\alpha$ -*conidendrin* 355–356  
 $\alpha,\beta$ -unsaturated carboxylic acids 409  
 $\alpha$ -diazoketone derivative 333  
 $\alpha$ -diazo- $\beta$ -keto sulfones 337  
 (+)-*ambruticin* 302–303  
 (+)-*ambruticin S* 331, 333–334  
*AMG 925* 219–220  
 amino acid dehydrogenases  
 (AADH) 410  
 7-aminocephalosporinic acid (7-  
 APA) 400  
*anacetrapib* 239–240  
*anastrozole* 362, 363  
 angiotensin II receptor blockers  
 (ARBs) 240  
*aperidine* 348  
*aprepitant* 82–83, 91, 94, 395  
*AR-A2* 211–212  
*Armindex*<sup>®</sup> 362  
 aryl bromide 191  
 4-aryl-*n*-butyraldehyde 182  
 3-aryloxy-2-propanolamines 389  
*AstraZeneca* 188  
 asymmetric Michael reaction 158  
*atorvastatin* 393, 397–398  
*ATSP-7041* 279, 281  
*avitriptan* 62–63  
*axitinib* 57–59, 190–191  
 aza-diketopiperazines (aza-DKPs) 102  
*AZD1480* 64–65  
*AZD3409* 188–189  
*AZD5423* 156–157  
*AZD8926* 139, 140, 248–249  
 azomethine ylides 302–304
- b**  
*baclofen* 162, 347–348, 398–399  
*balanol* 283–284  
*bendamustine hydrochloride* 106  
 benzoxazole 245  
 4-benzyloxy-propiofenone 368  
 benzyne dienes 296  
 berberine bridge enzyme (BBE) 404  
 $\beta$ 2-adrenergic receptor agonists 91  
 $\beta$ -aminoacrylate analogs 78  
 $\beta$ -blockers 389  
 $\beta$ -keto ester 237  
 $\beta$ -lactams 400  
 bicyclic  $\beta$ -lactams 12  
*BI-201302* 272–273  
*BILN-2061* 55, 272, 376  
*bimatoprost* 160, 293  
 biocatalysis  
 attributes of 387  
 C–X bond formation  
 $\alpha$ -chiral aldehyde 408  
 $\alpha,\beta$ -unsaturated carboxylic  
 acids 409  
 DERA catalyses 403  
 enantioselective cyanohydrin  
 synthesis 405  
*ephedrine* and pseudo-*ephedrine*  
 synthesis 404  
*glasdegib* 407  
 halohydrin dehalogenase  
 (HHD) 410  
*levomilnacipran* synthesis 404  
*niraparib* 407  
 $\omega$ -transaminases 406  
*vernakalant* via reductive  
 amination 409  
*zanamavir* synthesis 402  
 hydrolysis and reverse hydrolysis  
 (*S*)- $\alpha$ -aminoindane 392  
 $\beta$ -blockers (*S*)-*propranolol*  
 synthesis 389  
*Candida antarctica* lipase B  
 (CAL-B) 388

- cephalexin* 390  
 $\gamma$ -amino acids 393  
 glutaryl acylase 391  
*naproxen* synthesis 389  
*(S)*-1-phenylethylamine 391  
*ramipril* 390  
*valaciclovir* via transesterification  
     synthesis 394  
 industrial application 387  
 oxidation 399  
 reduction 394  
*Biotage* 33  
 bis-tetrahydrofuranlyl (bis-THF)  
     moiety 152  
*BMS-180048* 62  
*BMS-247243* 195  
*BMS-986097* 167–168  
*boceprevir* 399–400  
 boomerang catalysts 35  
 Bosch, Carl 3  
*BRL 55834* 116–117  
 2-bromo-6-methoxynaphthalene 176  
 bromonaphthalene  
     derivative 214  
 1-(4-bromophenyl)-2,2,2-  
     trifluoroethanone 203  
 3-bromoquinoline 194  
 Bruton's tyrosine kinase (BTK)  
     inhibitor 206  
 Buchwald–Hartwig reaction  
     *ALB 109780* synthesis 218  
     *(R)*-3-aminopentanenitrile 210  
     AstraZeneca's synthesis 211  
     bromonaphthalene  
         substrate 212  
     CCK 1R receptor agonist 213  
     cholecystokinin (CCK) 1R receptor  
         agonist 212  
     copper catalysts 210  
     Cu-Catalyzed C–N coupling  
         reaction 215  
     8-hydroxyquinoline 220  
     macrocyclic integrase  
         inhibitor 223–224  
     Pd-Catalyzed amination  
         reaction 214  
*buphenine* 269, 368
- c**  
*candesartan cilexetil* 240–241  
*Candida antarctica* lipase B  
     (CAL-B) 25, 388  
 cannabinoid-1 receptor (CB1R) 216  
 carbonyl groups 84  
 carbonyls 133  
 carbonyl ylides 307  
 catalysis and prerequisites  
     API synthesis developments 2  
         asymmetric  
             *cis*-dihydroxylation 16  
         asymmetric hydrogenation  
             reaction 14  
         asymmetric synthetic methods 11  
     bicyclic  $\beta$ -lactams 12  
     biotransformation 20  
     carbonic anhydrase inhibitor 20  
     carbonyl groups 13  
     CBS reduction 15  
     C–C coupling reactions 19  
     commercial applications 15  
     cyclopropanation reaction 11  
     Haber–Bosch (H–B) process 3  
     heterogeneous catalytic processes 3  
     hydroformylation 6  
     Jacobsen–Katsuki epoxidation 15  
     Mizoroki–Heck reaction 9, 18  
     multi-functional groups and  
         stereocenters 11  
     Negishi-coupling reaction 19  
     nickel carbonyl catalyst 6  
     organocatalysis 9, 10  
     Pd-catalyzed coupling reaction 9  
     physico-chemical behaviour, of  
         oxygen and hydrogen 4  
     RhCl(PPh<sub>3</sub>)<sub>3</sub> catalyst 7  
     Ru catalysts 13  
     Sharpless–Katsuki  
         epoxidation 16, 17  
     Suzuki–Miyaura coupling  
         reaction 19  
     TiCl<sub>3</sub> catalyst 7  
     Wacker reaction 5  
     cleaner reaction conditions 1  
     catalyst immobilization 25  
     catalyst recycling 45

- catalytic cross-coupling reactions
  - allylic substitution reactions 234
  - antimitotic agent 227
  - aryl bromide and propargyl
    - alcohol 228
  - aryl chloride intermediate and
    - tert*-butylacetylene 226
  - 3-bromo-4-methylbenzoic acid 232
  - Buchwald–Hartwig reaction 210
  - C–H activation processes 239
  - diastereoselective synthesis 230
  - drug candidate 228
  - eniluracil* synthesis 225–226
  - farnesyl transferase inhibitor 226
  - fungolimod* synthesis 224–225
  - Heck–Mizoroki reaction 176
  - imidazole 479754 229
  - oxidative C–C bond formation 248
  - pyrrolquinolone
    - PHA-529311* 229–230
  - Suzuki–Miyaura coupling
    - reactions 195, 224
  - terbinafin* synthesis 224–225
  - TRPV1 antagonist 226–227
  - Wyeth's synthesis of
    - GRN-529* 230–231
- catalytic cyclopropanation reactions
  - metal catalyzed processes
    - $\alpha$ -diazo- $\beta$ -keto sulfones 337
    - (+)-*ambruticin S* 331
    - CPA 333
    - Cu-catalyzed intramolecular arene
      - cyclopropanation reaction 333
    - Cu-catalyzed intramolecular
      - diastereoselective reaction 323
    - cyclopropyl carboxylic acid
      - derivative 324
      - (-)-*desoxyseroline* 331
      - (+)-*digitoxigenin* 338
      - LY2140023* synthesis 328
    - serotonin reuptake inhibitor 324
    - tandem continuous flow
      - procedure 324
    - TRPV1 antagonists 333
    - synthetic methods 322
  - catalytic process design
    - API manufacture, catalytic reactions
      - batch operations 49
      - continuous flow operations 63
    - heterogeneous and homogeneous
      - catalysts
        - adsorption/desorption
          - mechanism 33
        - boomerang catalysts 35
        - encapsulated/immobilized Pd
          - catalysts 33
        - hydrogenation reactions 33
        - immobilized and encapsulated
          - catalysts 35
        - metathesis reactions 35
    - product safety and regulatory
      - requirements 36–37
    - residual metals, control of
      - catalyst recycling 45
      - design of experiment
        - (DoE) 43–44
      - extraction and scavenging
        - 38–40
      - filtration and adsorption 38
      - organic solvent nanofiltration
        - (OSN) 41–42
      - scalability, safety and
        - environmental aspects 46–48
  - catalytic reductions
    - nitro units 104, 106–107
    - organocatalysts 103
  - cathepsin K inhibitor 203
  - cathepsin S inhibitor 78
  - CEP-33779* 222–223
  - cephalexin* 390, 391
  - cephalosporin C* 400–401
  - cethromycin* 194
  - (+)-*cetiedil* 354
  - C–H bond insertion reaction
    - aperidine* synthesis 348
    - (+)-*cetiedil* synthesis 354
    - (-)-*decursivine* 345
    - dictyodendrins synthesis 343
    - D-threo-methylphenidate*
      - synthesis 355
    - (-)-*ephedradine A* 343
    - (-)-*epi-conocarpan* and
      - (+)-*conocarpan* 344

- $\gamma$ -aminobutyric acid (GABA) 347  
 (–)-*hamigeran B* 353  
 (+)-*imperanene* 355  
 (–)-*incarviateone A* 350  
 mechanism 342  
 (+)-methoxyphenylkainic acid and  
   (+)-phenylkainic acid 345  
*methylphenidate* 355  
*pradimicinone* 349  
 (+)-*przewalskin B* 349  
 (+)-*przewalskin synthesis* 350  
 (*R*)-(–)-*rolipram* 342  
 Ru and Cu complexes 342  
 (–)-*serotobenine synthesis* 345–346  
 tetrionic acid derivatives 348  
 transition-metal-carbenoid  
   intermediate 342  
 (–)-*virginiamycin M<sub>2</sub>* synthesis 351  
 chiral (1*R*,2*S*)-1-amino-2-  
   vinylcyclopropanecarboxylic  
   acid (ACCA) moiety 376  
 chiral diaminophosphine oxide ligand  
   (DIAPHOX) 238  
 (–)-*chloramphenicol* 126, 127  
 chlorodeazapurine 203  
 cholecystokinin (CCK) 1R receptor  
   agonist 212  
 chronic hepatitis C virus (HCV)  
   infection 167  
*CI-1034* 197  
*cilastatin* 11–12  
*ciluprevir* 39, 41, 55–57, 272, 376  
*cinacalcet* 98, 177–178  
*CJ-15161* 215–216  
*clofazimine* 107  
*clopidogrel* 405  
*colchicine* 307–308  
 (+)-*conocarpan* 344  
 Corey, EJ 291  
*CP-724* 714, 186, 188  
 Crestor<sup>®</sup> 19  
*crizotinib* 53, 86, 200  
 Cu(II) catalyst 307  
*cyclizidine* 11  
 [2+2] cycloaddition reaction 312  
   *lobucavir* 312  
   *orlistat* 312  
 [2+2+2] cycloaddition reaction 313–315  
 [3+2] cycloaddition reaction  
   azomethine ylides 302  
   carbonyl ylides 307  
   Click reactions 308  
   HCV inhibitor 305  
   *RG7388 synthesis* 306  
 [5+2] cycloaddition reaction 315–316  
 cycloaddition reactions  
   CuAAC reaction 308  
   Diels–Alder reaction 291, 292  
 cyclopropylamine intermediate  
   (1*R*,2*S*)-2-(3,4-difluorophenyl)  
   cyclopropylamine (CPA) 333
- d**
- danoprevir* 272–273  
 Daxas<sup>®</sup> 368  
*dapoxetine* 94–95  
 (–)-*decursivine* 345  
 dehydrative cyclization 161  
 deoxyribose phosphate aldolase (DERA)  
   catalyses 403  
 design of experiment (DoE) 43, 67  
 (–)-*desoxyeseroline* 331  
 Dess–Martin periodinane oxidant 248  
*dextromethorphan* 87–88  
*DG-041* 186, 188  
 1,2-diaminopropane (1,2-DAP) 191  
*diazepam* 23  
 Diels–Alder (DA) reaction 291  
   carbogens, synthesis of 292  
   commercial prostaglandin APIs 294  
   disadvantages 293  
   *ifetroban sodium* 296  
   6-membered ring formation 291  
   *MK-1256* 297  
   *oseltamivir phosphate synthesis* 295  
   *paclitaxel* 298  
   prostaglandins 293  
   *taxadienone* 298  
   1,2,3-triazole intermediate 295  
   Woodward–Hoffmann symmetry  
     rules 292  
 (+)-*digitoxigenin* 338  
 diketoreductase (DKR) 397  
*diltiazem* 119–120

- dinoprost* 159–160, 293  
*dinoprostone* 293  
 1,4-dioxane 206  
 (+)-*discodermolide* 150  
*discodermolide* 151–153, 196  
*donezepil* 360, 361  
*dorzolamide* 14–15, 20, 90  
*dronedarone* 366–367  
*D-threo-methylphenidate* 355  
 dual catalysis 24  
 (*S*)-*duloxetine* 96  
 dynamic kinetic asymmetric  
     transformations (DYKAT) 24
- e**
- EDP-420 365  
*efavirenz* 22, 374  
 Efivar<sup>®</sup> 374  
*elbasvir* 270  
*eletriptan* 178–179  
*emicerfont* 215, 217  
 ene reductases (ERED) 398  
*eniluracil* 225–226  
 (–)-*ephedradine A* 343  
*ephedrine* 160, 404  
 (–)-*epibatidine* 170  
 (–)-*epi-conocarpan* 344  
*epoprostenol* 293  
*eribulin* 150–151  
 (–)-*erinacine B* 338  
*erogorgiaene* 168  
 Ertl, Gerhard 3  
*esomeprazole* 17, 18, 127, 131–132, 402  
*estrone* 299, 314–315  
 ethyl acrylate 192, 194  
 ethylene 176, 189
- f**
- Fanapt<sup>®</sup> 361  
 farnesyl transferase inhibitor 188, 226  
*febuxostat* 200, 247  
*fendiline* 104  
*fesoterodine* 54–55  
*filibuvir* 230–231  
 *fingolimod* 224–225, 377–378  
 *fingolimod* (FTY720) 377–378  
 *firategrast* 274  
 Fischer–Tropsch reaction 6  
 (*R*)-*fluazifop* 410  
 4-fluorostyrene 189  
 (*R*)-*flurbiprofen* 398  
 *fluoxetine* 96  
 *FR901512* 150  
 Friedel–Crafts acylation 23  
 *FTY720* 377–378
- g**
- gabapentin* 162, 347  
 *gandotinib* 244  
 *garenoxacin* 201  
 $\gamma$ -aminobutyric acid (GABA) 241, 347  
 $\gamma$ -butyrolactone 240  
 *GDC-0084* 208–209, 364  
 *GDC-0994* 134  
 *glasdegib* 407  
 *glecaprevir* 272–273  
 glutaryl acylase 391  
 glycogen synthase kinase-3 $\beta$  (GSK3 $\beta$ )  
     inhibitor 248  
 *grazoprevir* 269–271, 376  
 *GRN-529* 230–231  
 Grignard reagents 148  
 Grignard, Victor 7  
 *GSK1360707* 209  
 *GSK966587* antimicrobial agent 115  
 *GSK966587* 114–115, 192  
 *GW 0430* 92
- h**
- Haber–Bosch (H–B) process 3  
 Haber, Fritz 3  
 halichondrins 150  
 haloalkane dehalogenase 405  
 halohydrin dehalogenase 410  
 haloperoxidases 401  
 (–)- *hamigeran B* 353  
 healthcare services 1  
 Heck–Mizoroki reaction  
     2-acetamido-5-bromopyridine and  
     ethylene 189  
 $\alpha_v\beta_3$  antagonist 192  
 antibiotic  *ABT-773* 194  
 *axitinib* 190  
 *AZD3409* synthesis 189

- benzazepine compound *SB-273005*  
 synthesis 186
- 2-bromo-6-methoxynaphthalene and ethylene 176
- 3-bromoquinoline and ethyl acrylate 194
- chiral *N*-benzylated-3-acylindole 184  
*cinacalcet* 177  
*DG-041* synthesis 188
- double zwitterion *BMS-247243* 195  
*eletriptan* 178
- ester hydrolysis 193
- glycine antagonist 182
- H<sub>1</sub>–H<sub>3</sub> antagonist 183
- iodo-indole derivative and allylic alcohol 193
- ketolide antibiotic *ABT-773* 194
- leukotriene synthesis 177
- methyl 2-acetamidoacrylate 184
- methyl 2-chloro-5-nitrobenzoate and 4-fluorostyrene 189
- neбиволol* 181
- optically active diol 189–190
- paclitaxel* synthesis 180
- Pd-catalyzed coupling reactions 176
- Pd(OAc)<sub>2</sub> and P(*o*-Tol)<sub>3</sub> 188
- pemetrexed disodium* synthesis 182
- peroxisome proliferator-activated receptor (PPAR $\gamma$ ) inhibitor 183
- phosphine-free Heck–Mizoroki reaction 185
- resveratrol* 179
- rilpivirine* 180
- second-generation Heck–Mizoroki route 186
- tricyclic indole-2-carboxylic acids 193
- trimercaptotriazine (TMT) 183
- unnatural amino acid 6-dimethyltyrosine 2, 184
- Henry reaction 10
- hepatitis C virus (HCV) inhibitor 304
- hetero-Diels–Alder (hDA) reaction  
 (+)-*ambruticin* 302–303
- imidodiphosphorimidate Brønsted acid catalysts 302
- Jacobsen catalyst 302
- 6-membered nitrogen-containing heterocycles 299
- nomenclature of 300
- rifamycin S* 299
- SDZ SER-082* 300
- UK-156406* 300
- vabicaserin* 301
- homogenous catalytic hydrogenation 7
- horse liver alcohol dehydrogenase (HLADH) 394
- HS-10168* 203–204
- human immunodeficiency virus 1 (HIV-1) protease inhibitors 152
- hydroformylation reaction  
 bicyclic lactam and application 101  
*cinacalcet* 98  
 Roche aldehyde synthesis 100
- hydrogenation  
 alkenes  
 $\alpha,\beta$ -unsaturated carboxylic acids, esters, itaconates 79  
 enamides 77  
 asymmetric catalytic hydrogenation processes 77  
 carbonyl groups 84  
 of imines 87  
 transfer hydrogenation  
 of ketones 88  
 on imines 92
- hydrolytic kinetic resolution (HKR) 117
- 8-hydroxyquinoline 220
- i**
- ibuprofen* 13, 23
- idasanutlin* 305
- ifenprodil* 368, 369
- ifetroban sodium* 296–297
- iloperidone* 361–362
- ilepratil* 98–99
- iloprost* 293
- imatinib* 22
- imidazotriazine 191, 241
- imines 87
- (+)-*imperanene* 355, 356



- (-)-*incarviateone A* 350  
 (+)-*indacrinone* 359, 370  
 (+)-*indatraline* 354  
*indinavir* 16, 401  
 International Council of Harmonization (ICH) 36  
 International Conference on Harmonization (ICH) guidelines 311  
 5-iodouracil substrate 225  
*irbesartan* 241–242  
*HS-10168* 203–204  
*isoproterenol* 155
- j**  
 Jacobsen–Katsuki epoxidation 15, 116  
 Janus-associated kinase 2 (JAK2) 203  
 Januvia<sup>®</sup> 19, 59
- k**  
 Kagan–Modena method 127  
 (S)-*ketoprofen* 394–395  
 ketoreductases (KREDs) 394, 395  
 Kulinkovich reaction 322
- l**  
*L-679,336* 125  
*L-699,392* 18, 177  
*L-733,060* 125–126  
*L-784,512* 122–123  
*lansoprazole* (LPS) 130, 131  
 (R)-*lansoprazole* 130  
*lapatinib* 202  
*latanoprost* 293  
*L-azatyrosine* 78  
*L-carnitine* 397  
*L-DOPA* 13, 76  
*lete rmovir* 375–376  
*levcromakalim* 120–121  
*levofloxacin* 13–14, 85  
*levomilnacipran* 329–330, 404  
*lidocaine hydrochloride* 23  
 Lipitor<sup>®</sup> 19  
*lobucavir* 312, 314  
*lofexidine* 405  
 (S)-*lofexidine* 406  
*losartan* 19, 199–200, 241–242
- lowest unoccupied molecular orbital (LUMO) 292  
 L-Valine methyl ester 394  
*LY2140023* 328–329  
*LY235959* 293–294  
*LY2497282* 78  
*LY2623091* 205–206  
*LY2801653* 65  
 Lyrica<sup>®</sup> 375
- m**  
 (S)-MA20565 90  
 macrocyclic integrase inhibitor 223  
 (-)-*malyngolide* 337  
 Mannich reaction 10  
*maraviroc* 135–136  
 matrix metalloprotease (MMP-3) inhibitor 80  
*mavatrep* 207–208  
 (-)-menthol 76  
*merestinib* 65–67  
 methyl 2-chloro-5-nitrobenzoate 189  
 methyl 2-iodobenzoate 177  
 (+)-*methoxyphenylkainic acid* 345  
*methylphenidate* 355  
*metolachlor* 76  
 Michael addition 10  
 (S)-*miconazole* 155  
 mineralocorticoid receptor (MR) antagonist 205  
 Miyaura borylation reaction 205–206  
 Mizoroki–Heck (M–H) reactions 9, 18  
*MK-0417* 14–15  
*MK-0822* 378  
*MK-1256* 296, 298  
*MK-3207* 378–380  
*MK-5172* 269  
*MK-6325* 272  
*MK-7009* 267  
*MK-8742* 205, 270  
*MK-8825* 380  
*MK-8831* 271–272  
 (R)-*modafinil* 131  
*modithromycin* 235, 365  
 monoamine oxidase (MAO) 399  
*montelukast* 86, 176–177, 395–396



- Multaq<sup>®</sup> 366  
 multiwalled carbon nanotubes  
 (MWNT) 156
- n**
- naproxen* 13–14, 18, 176–177, 389  
 (*S*)-*naproxen* 82, 389  
*nebivolol* 181  
 Negishi coupling reaction 18  
*nemonapride* 380, 381  
 neuropeptide Y (NPY)-5 receptor  
 antagonist 196  
*nevirapine* 198  
*niraparib* 220, 407, 408  
*N*-methyl-D-aspartate (NMDA) 2B  
 receptor 85  
*N*-methyl-*N*-nitrosourea 337  
 Non-asymmetric dihydroxylation  
 reactions 125  
*noremopamil* 114  
 (*S*)-*noremopamil* 114, 115  
 Nozaki–Hiyama–Kishi (NHK)  
 reaction 149  
*NPS 53574* 140  
*NPS R-568* 103  
*N*-sulfonated diamine- $\eta^6$ -arene  
 ruthenium catalyst 89  
 nucleophilic addition reaction 147  
 nucleophilic methods 119  
*N*-vinylphthalimide 192  
 Nylidrin<sup>®</sup> 368
- o**
- odanacatib* 203–204, 378, 379  
 olefin aminohydroxylation 125  
 olefin dihydroxylation 121  
 olefin epoxidation  
 Jacobsen–Katsuki asymmetric  
 epoxidation 116  
 nucleophilic methods 119  
 organocatalytic methods 119  
 Sharpless–Katsuki asymmetric  
 epoxidation 113  
*olmesartan medoxomil* 241–242  
*olopatadine hydrochloride* 232  
 Olysio<sup>®</sup> 267  
*omapatrilat* 98–99  
*ombitasvir* 272  
*omeprazole* 17, 127, 130, 131  
 (*S*)-*omeprazole* 130  
 one variable a time (OVAT)  
 approach 43  
*OPC-29030* 127–128  
 organic solvent nanofiltration (OSN) 41  
 organocatalysts 103  
 organocatalytic methods 119  
*orlistat* 87, 312, 314  
*oseltamivir phosphate* 295–296  
 Ostwald, Wilhelm 2  
*OSU 6162* 196  
 oxazaborolidine reductions 94  
 oxidation  
 asymmetric catalytic oxidation 113  
 carbonyls 133  
 olefin aminohydroxylation 125  
 olefin dihydroxylation 121  
 olefin epoxidation  
 Jacobsen–Katsuki asymmetric  
 epoxidation 116  
 nucleophilic methods 119  
 organocatalytic methods 119  
 Sharpless–Katsuki asymmetric  
 epoxidation 113  
 oxidative dehydrogenations  
 (OD) 139  
 sulfur oxidation 127  
 oxidative dehydrogenations (OD) 139
- p**
- paclitaxel* 125, 180, 298  
*pacritinib* 273–274  
*palbociclib* 194  
*paritaprevir* 272–273  
 (–)-*paroxetine* 163–164  
*pemetrexed disodium* 182  
*perindopril* 409  
 phase transfer catalysis (PTC)  
 achiral PTCs  
*anastrozole* synthesis 362  
 4-benzyloxy-propiofenone  
 synthesis 369  
*donepezil* 360  
*dronedarone* synthesis 366–367  
*GDC-0084* synthesis 364

- phase transfer catalysis (PTC) (*contd.*)
- iloperidone* synthesis 361
  - modithromycin* synthesis 365
  - pharmaceutical
    - manufacturing 360
  - ranolazine* synthesis 363
  - roflumilast* synthesis 368
  - tenofovir disoproxil* synthesis 366
  - viloxacine* synthesis 361
- asymmetric PTCs
- ACCA synthesis 377
  - alkylation and nitro-Mannich reactions 372
  - chiral guanidinium and pentanidium 372
  - cinchonidine and cinchonine selection 370
  - efavirenz* synthesis 374
  - fingolimod* (FTY720) synthesis 377
  - letermovir* synthesis 376
  - MK-3207* synthesis 378
  - MK-8825* synthesis 380
  - nemonapride* synthesis 380
  - novel chiral spiro ammonium and phosphonium catalysts 371
  - odanacatib* synthesis 379
  - (*S*)-*pregabalin* synthesis 375
  - (+)-*indacrinone* synthesis 359, 370
  - organic/aqueous liquid-liquid mixture 359
  - solid-liquid conditions 359
- phenpyramine 96–97
- phenylephrine 85
- (*S*)-1-*phenylethylamine* 391
- (+)-*phenylkainic acid* 345
- 1-phenyl-3-oxabicyclo[3.1.0]hexan-2-one 329
- phosphites 98
- phosphonites 98
- polymerase chain reaction (PCR) 10
- potassium 6-trimethylbenzenesulfonate (TMBSK) 2, 4, 240–241
- pradimicinone* 349
- (±)-*preclamol* 246–247
- (*S*)-*pregabalin* 375, 399
- pregabalin* 81, 82, 162, 398
- (+)-*preussin* 156
- process analytical technology (PAT) 66, 68
- (*R*)-1,2-propanediol 85
- (*2S*)-*propranolol* 14, 122, 123
- prostaglandins 165, 293
- (+)-*przewalskin B* 349
- pseudo-*ephedrine* 404
- (1*R*,2*R*)- pseudo-*ephedrine* 403
- Pseudomonas fluorescens* esterase I (PFEI) 393
- pyridazinone 214
- pyrrolquinolone  
PHA-529311 229–230
- q**
- quality assurance (QA) 64
- quality by design (QbD) 49, 64, 68
- quinoline 44, 52, 140, 141
- (+)-*Quebrachamine* 283
- r**
- rac-tolterodine* 97–98
- rac-modafinil* 132
- ramipril* 390
- Ranexa<sup>®</sup> 363
- ranolazine* 363
- rasagiline* 392
- Rasilez<sup>®</sup> 275
- rebeccamycin* analog 249
- (*S,S*)-*reboxetine succinate* 114, 115
- Relacatib 264–267
- Reppe, Walter 6
- resveratrol* 179
- RG7388 305–307
- Rh-catalyzed addition reaction 149
- rifamycin S* 299
- rilpivirine* 180–181
- ring-opening-metathesis polymerization (ROMP) 7
- ritodrine* 269, 368
- ritonavir* 272
- rivastigmine* 85–86, 94, 103–105, 406
- Ro 67-8867 67
- roflumilast* 368

*rolapitant* 277–278  
 (R)-(-)-*rolipram* 164, 342–343  
 (R)-*rolipram* 164  
 (S)-*rolipram* 164–165  
*rolipram* 162  
*rosuvastatin* (Crestor) 137, 138, 403  
*ruxolitinib* 203  
 RWJ-53308 82, 84

**S**

Sabatier, Paul 3  
 (R)-*salmeterol* 154  
*saxagliptin* 410  
 SB-1317 274  
 SB-1518 273–274  
 SB-273005 80–81, 185–186  
 SB-462795 264  
 SB-683699 274  
 SCH-619734 277  
 SDZ NKT 78 343  
 SDZ SER-082 300–301  
 selective serotonin reuptake inhibitor (SSRI) 163  
 serine palmitoyl transferase (SPT) inhibitor 243–244  
 (-)-*serotobenine* 345–346  
*sertraline* 88, 94–95  
 (4S)-*sertraline* 88  
*cis*-(1S,4S)-*sertraline* 88–89  
 serotonin-norepinephrine reuptake inhibitor (SNRI) 329  
 Sharpless–Katsuki system 17  
 Sharpless–Katsuki Ti-catalyzed epoxidation 14  
*sibenaedet hydrochloride* 133  
*simeprevir* 267–268, 376  
 Simmons–Smith reaction 321  
 Singulair® 18, 19, 86, 176, 395–396  
*sitagliptin* 59–62, 78–79, 407  
*solithromycin* 309–313  
 (S)-*sotalol* 155  
*statine* 84  
 sulfur oxidation  
   titanium, molybdenum catalysts 127–128, 130  
   tungsten catalysts 132  
   vanadium catalysts 127–128, 130

*sulindac* 127–128  
 Sustiva® 374  
*suvorexant* 92–93  
 Suzuki–Miyaura reaction 9, 18, 22, 66  
   2-amino-5-phenylpyrazine 196  
 API *lapatinib* 202  
 approach 51  
 borylation reactions 205  
 bromosulfone and pyridyl borane substrate 196  
 Bruton's tyrosine kinase (BTK) inhibitor 206  
 chloropyrimidine and arylboronic ester 208  
*crizotinib* synthesis 200  
 double borylation 205  
 ethyl 3-[4-(1,1-dimethylethyl)phenyl]-1H-indole-2-carboxylate 197  
*febuxostat* synthesis 200  
*garenoxacin* synthesis 201  
 GlaxoSmithKline's synthesis 209  
*losartan* synthesis 199  
*nevirapine* analog 198  
 Ni catalysts 195  
 P(o-Tol)<sub>3</sub> 198  
*ruxolitinib* 203  
 1,3,4-trifluorophenyl-6-boronic acid 197  
 trithiocyanuric acid 197  
*vemurafenib* and *abiraterone acetate* 202

**t**

*tafamidis* 247  
*tafluprost* 159–160, 293  
 (-)-*tangutorine* 238  
*taranabant* 79, 80, 216–217  
*tasimelteon* 117–118, 123, 124  
 Taube, Henry 7  
*taxadienone* 298–299  
 Taxol® 125, 298  
 TCM 20 185  
 Technivie® 272  
 Tekturna® 275  
*telaprevir* 399–400  
*telcagepant* 149, 169–170

*telmisartan* 22–23  
 TEMPO/NaClO<sub>2</sub> oxidation  
     procedure 138  
*tenofovir disoproxil* 366  
*terbinafine* 149, 224–225  
*tert*-butylhydroperoxide  
     (TBHP) 114  
*texaline* 248  
 (+)-*thiamphenicol* 126, 127  
*thienamycin* 12  
 (*R*)-*tiagabine* 107  
*ticagrelor* 333, 336–337  
*TIQ-A* 65–66  
*TMC-435* 267  
*tofacitinib* 107  
*torcetrapib* 210  
 transfer hydrogenation  
     on imines 92  
     of ketones 88  
 transient receptor potential vanilloid-1  
     (TRPV1) antagonists 207  
*travoprost* 160, 293  
 tricyclic indole-2-carboxylic  
     acids 193  
 1,3,4-trifluorophenyl-6-boronic  
     acid 197  
 2,4,6-trimercaptotriazine (TMT) 40  
 trithiocyanuric acid 197  
 Tsuji, Jiro 8  
 Tsuji–Trost Allylation 235  
 tungsten catalysts 132

**u**

*UK-370,106* 81  
*UK-156406* 300, 302  
*Umbelliferone* 282  
*ustiloxin D* 237

**v**

*vabicaserin* 301  
*valaciclovir* 394  
*valsartan* 50, 51, 52, 200, 241–242  
*valsartan* 49–53  
 vanadium catalyst 131  
 Vanihep<sup>®</sup> 267  
*vaniprevir* 267–270, 376  
 Vanihep<sup>®</sup> 277  
 Varubi<sup>®</sup> 277  
*vemurafenib* 201, 202  
*venlafaxine* 354  
*vernakalant* 409  
 Vicilan<sup>®</sup> 361  
 (+)-*vigulariol* 352  
 Viekira Pak<sup>®</sup> 272  
*viloxacine* 361  
 Viread<sup>®</sup> 366  
 (–)-*virginiamycin M2* 351  
*vismodegib* 107  
 Vivalan<sup>®</sup> 361

**w**

*warfarin* 162  
 Woodward–Hoffmann symmetry  
     rules 292

**y**

YM-09151 380  
 Yutopar<sup>®</sup> 368

**z**

*zanamavir* 402  
*ZD2249* 128  
 Zepatier<sup>™</sup> 269  
 Ziegler, Karl 7  
*zolpidem* 250